Accueil・Liste d'Actions・Vaxcyte Inc

Vaxcyte Inc

Ouvert

SecteurSoins de santé

58.03 -1.01

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

56.95

Max

60.14

Chiffres clés
By Trading Economics
Revenu	-284M -605M
BPA	-1.97
Employés	507
EBITDA	22M -292M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+94.24% upside

Dividendes
By Acuity
Prochains Résultats	2 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	944M 8.7B
Ouverture précédente	59.04
Clôture précédente	58.03

Sentiment de l'Actualité

By Acuity

50%

171 / 340 Classement par Healthcare

Vaxcyte Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 août 2026, 19:46 UTC

Vaxcyte Inc shares are higher today, supported by broader market gains following positive sentiment from the recent inflation report. The stock remains above its 20-day moving average.

11 août 2026, 23:11 UTC

Vaxcyte Inc shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the price action.

10 août 2026, 19:56 UTC

Vaxcyte Inc shares are higher, continuing gains since Friday's close, reaching a peak earlier in the session. No specific news was identified for the move.

7 août 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 août 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 août 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 août 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 août 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 juil. 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 juil. 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 juil. 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 juil. 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 juil. 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 juil. 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 juil. 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Comparaison

Variation de prix

Vaxcyte Inc prévision

Objectif de Prix

By TipRanks

94.24% hausse

Prévisions sur 12 Mois

Moyen 114.33 USD 94.24%

Haut 163 USD

Bas 75 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

171 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.